RCT: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels.

Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial – Nature Medicine

Commentary on Twitter

The SAVE-MORE phase 3 study demonstrates the efficacy of anakinra, an IL-1α/β inhibitor, in patients with COVID-19 and high serum levels of soluble plasminogen activator receptor, according to a @NatureMedicine paper. https://t.co/aM5teLMipK pic.twitter.com/bTVNqbBOcv

— Nature Portfolio (@NaturePortfolio) September 3, 2021